Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | GPR174 | Q9BXC1 | 4/20 | 0.46 |
| ▸ | NPY1R | P25929 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPY2R | P49146 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL521847 | 1.00 | MAPT (0.52) | MAPTALDH1A1LMNAGAACYP1A2 | |
| SCHEMBL521317 | 0.88 | MAPT (0.56) | MAPTALDH1A1LMNAGAACYP1A2 | |
| SCHEMBL521316 | 0.88 | MAPT (0.56) | MAPTALDH1A1LMNAGAACYP1A2 | |
| SCHEMBL521107 | 0.83 | MAPT (0.51) | MAPTALDH1A1LMNAGAACYP1A2 | |
| SCHEMBL521106 | 0.83 | MAPT (0.51) | MAPTALDH1A1LMNAGAACYP1A2 | |
| SCHEMBL520843 | 0.82 | JAK2 (0.44) | MAPTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL520842 | 0.82 | JAK2 (0.44) | MAPTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL2206124 | 0.82 | MAPT (0.51) | MAPTALDH1A1LMNAGAACYP1A2 | |
| SCHEMBL3345297 | 0.81 | MAPT (0.54) | MAPTALDH1A1LMNAGAACYP1A2 | |
| SCHEMBL30020102 | 0.80 | MAPT (0.69) | MAPTALDH1A1LMNAGAACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | MAPT 3109/4885ALDH1A1 779/4885LMNA 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.